Recent studies are finding that drugs such as LSD and psilocybin can help to alleviate depression, anxiety and addiction. –Wall Street Journal
With the pot stock bubble deflating, investors are wondering where the next big profit opportunity is going to come from. Many experts see psychedelics and specifically psilocybin medicine as the next wave of profits after cannabis. This new breakout industry has the potential to transform the $15 billion antidepressant market and create many cures for mental health issues, as well as create many new millionaires.
The Canadian Company with the First Mover Advantage
Currently there is only one Canadian publicly traded Company that is focused on capitalizing on the psychedelic boom. Roadman Investments Corp. (TSX-V: LITT, OTC: RMANF, Forum) is a Venture Capital and Corporate Advisory firm that aims to give investors the opportunity to have exposure to pre-IPO psychedelic companies that are developing innovative products and treatments utilizing medicinal mushrooms and psychedelic compounds. The Company’s mission is to place capital to the leading innovators that are working towards helping people with mental health problems with new breakthrough treatments.
In the last 30 days, the Company has seen massive volume after it announced investments in the functional medicinal mushroom market and an agreement with another company that is focused on the development of cGMP production and formulation of bioactive compounds extracted from plants and fungi.
Roadman is well-capitalized and has leading industry advisors including a renowned psychopharmacology expert and Kevin Matthews, the man responsible for the success of its decriminalization in Denver.
Psychedelic Medicine is creating a foothold in the scientific community
Research has found that psilocybin and other psychedelic compounds offer unique qualities to treat serious mental health conditions. Psilocybin targets that receptors involved in adaptability, abstract thinking, thoughts and analysis and treatments with this medicine are showing lasting changes in many studies.
Preliminary studies from institutions like Imperial College of London, University of Zurich, Johns Hopkins, NYU and UCLA, suggest that psilocybin-assisted therapy could be a revolutionary treatment for:
• Addiction to Tobacco and Alcohol
• Depression and Anxiety in cancer patients
• General Depression
The FDA has already granted "breakthrough therapy" status to study psilocybin-assisted treatment for treatment-resistant depression. For a closer look at psychedelics, Stockhouse Editorial recently published - Why Psychedelics Look like the Next Billion-Dollar Business- an article assessing their properties and effectiveness.
Huge Addressable Market
It is estimated that one in six Americans takes some form of psychiatric drugs like antidepressants. The World Health Organization estimates that there are more than 300 million people worldwide who suffer with depression. Antidepressants are projected to generate nearly $17 billion by 2020 for this debilitating mental illness. In the US alone, treatment is projected to be worth $150 billion in overall value. The global Anti-Depressant market can be disrupted by chemicals found in mushrooms as treatments go mainstream.
The alternative medicinal market is rapidly growing outside of mainstream medicinal practices. Healthcare Intelligence Markets forecasts the market to generate a revenue of $210.81 billion by 2024.
Roadman’s Industry Experts and Advisors
Kevin Matthews, one of the leading medicinal mushrooms advocates and championed the successful campaign to decriminalize psilocybin in Denver. Kevin’s huge network in the alternative health space means access to the best medicinal mushroom companies in the world.
Anton Gomez-Escolar is the Company’s psychopharmacology expert that has a Masters Degree in Psychopharmacology from Spain’s largest university, Complutense University of Madrid, a certificate of Design and Interpretation of Clinical Trials from John Hopkins School of Public Health and a Drug Use, Policy and Health certificate from the University of Geneva.
Mr. Escolar’s technical understanding of neurobiology, psychopharmacology, drug safety and clinical trial development will allow Roadman Investments to better evaluate potential investments in biotech firms as well as help the Company provide advisory services to future investee’s or partners that need this expertise.
Roadman’s current Psychedelic Deals
Roadman states that their current focus is in acquiring assets in cultivation, distribution, consumer products, services and research and development in the medicinal mushroom and psychedelic sectors. Currently they have two agreements in place:
Altmed - AltMed is a Canadian alternative medicine business incubator, intellectual property (IP) aggregator and solutions provider; mandated with accelerating advancements in the alternative medicine arena. Altmed is currently focused on the development of cGMP production and formulation of bioactive compounds extracted from plants and fungi.
Roadman Investments has inked an initial advisory services agreement that permits them to provide advice for corporate actions, including reviewing potential transactions, assisting with alternative financing solutions, and facilitating introductions to strategic partners. The Company followed a similar strategy with Champignon brands were they signed an advisory agreement and then followed up with an investment in 90 days.
Champignon Brands - Champignon Brands Inc. is a Canadian based Company dedicated to promoting the cultivation and proliferation of high-quality medicinal mushrooms and health supplements. The Company is a member of the American Mushroom Institute and has functional tea beverages that incorporate organic teas with Cordyceps, Reishi and Lion’s mane mushroom extracts.
Roadman has invested $150,000 and the Company’s executives have been assisting the branding and in the product development and commercialization of their proprietary medicinal mushroom infused teas. The advisory agreement allows the Company to appoint a director, Inspect records, attend meetings and a right of first refusal in any future equity offerings at a price of $0.05 per share or higher.
A distinct strategy
Champignon Brands is producing a line of affordable products in a large market and is relatively alone in the playing field. The Company’s strategy is to create a legal medicinal mushroom business that is generating revenue and consumer interest.
These products utilize legal medicinal mushrooms with proven health benefits infused with organic tea. Tea is the most popular beverage in the world and also happens to be the best known delivery system for psilocybin mushrooms.
Roadman leadership forecasts a greater shift of legalization by 2022 and with an established brand, distribution and capital Champignon is planning on launching additional products that incorporate psychedelic compounds once the proper legal approvals are in place.
The landscape of decriminalization
After “What does it do?” the next question most people have about psychedelics is … “Where is it legal?”
Psilocybin is legal in the Netherlands, Jamaica, Brazil and Samoa. However just this year the State of Colorado voted in favor of Initiative 301, which resulted in Denver becoming the first US city to decriminalize psilocybin. Several weeks later, Oakland, California followed Denver and now Oregon is trying to get a similar measure on the ballot for 2020.
The passage of Initiative 301 has since driven a national discourse on the potential health benefits within psilocybin. Industry experts see mushrooms having untapped medical potential that could be as big as Cannabis especially considering the clinical studies showing the mushrooms effects on people struggling with depression and post-traumatic stress disorder.
Bottom Line
Roadman has the potential to become a dominant force in this fast-growing industry due to its first mover advantage and its connections to leading experts in the industry. It is evident that legalization is on the horizon and if this boom is anything like cannabis early stage investors have an opportunity for big profits.
roadmancorp.com
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.